Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Intralesional Influenza Vaccine for Patients With Melanoma
Sponsor: Carlo Contreras
Listed as NCT04697576, this PHASE1 trial focuses on Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage IA Cutaneous Melanoma AJCC v8 and remains actively recruiting participants. Sponsored by Carlo Contreras, it has been updated 9 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1
-
Aug 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Nov 2024 — Aug 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2022 — Aug 2023 [monthly]
Recruiting PHASE1
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Carlo Contreras
For direct contact, visit the study record on ClinicalTrials.gov .